Compare TALKW & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALKW | BMRN |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 10.4B |
| IPO Year | N/A | 1999 |
| Metric | TALKW | BMRN |
|---|---|---|
| Price | $0.00 | $57.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $88.22 |
| AVG Volume (30 Days) | 139.4K | ★ 2.1M |
| Earning Date | 02-20-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $181,291,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ N/A | $106.20 |
| Revenue Growth | ★ 31.50 | 17.62 |
| 52 Week Low | $0.00 | $49.26 |
| 52 Week High | $0.10 | $66.28 |
| Indicator | TALKW | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 59.45 |
| Support Level | N/A | $51.69 |
| Resistance Level | $0.01 | $58.29 |
| Average True Range (ATR) | 0.00 | 1.36 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 0.00 | 80.25 |
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.